Krebs, Matthew G. and Forster, Martin and Majem, Margarita and Peguero, Julio and Iams, Wade and Clay, Tim and Roxburgh, Patricia and Doger, Bernard and Bajaj, Pawan and Barba, Andres and Perera, Suvini and Mueller, Christian and Triebel, Frédéric (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5 (11): 100725. ISSN 2666-3643

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432